Adenosine A2A receptor

Structure

This protein is a member of the G protein-coupled receptor (GPCR) family which possess seven transmembrane alpha helices, as well as an extracellular N-terminus and an intracellular C-terminus. Furthermore, located in the intracellular side close to the membrane is a small alpha helix, often referred to as helix 8 (H8). The crystallographic structure of the adenosine A2A receptor reveals a ligand binding pocket distinct from that of other structurally determined GPCRs (i.e., the beta-2 adrenergic receptor and rhodopsin). Below this primary (orthosteric) binding pocket lies a secondary (allosteric) binding pocket. The crystal-structure of A2A bound to the antagonist ZM241385 (PDB code: 4EIY) showed that a sodium-ion can be found in this location of the protein, thus giving it the name 'sodium-ion binding pocket'.

Heteromers

The actions of the A2A receptor are complicated by the fact that a variety of functional heteromers composed of a mixture of A2A subunits with subunits from other unrelated G-protein coupled receptors have been found in the brain, adding a further degree of complexity to the role of adenosine in modulation of neuronal activity. Heteromers consisting of adenosine A1/A2A, dopamine D2/A2A and D3/A2A, glutamate mGluR5/A2A and cannabinoid CB1/A2A have all been observed, as well as CB1/A2A/D2 heterotrimers, and the functional significance and endogenous role of these hybrid receptors is still only starting to be unravelled.

The receptor's role in immunomodulation in the context of cancer has suggested that it is an important immune checkpoint molecule.

Function

The gene encodes a protein which is one of several receptor subtypes for adenosine. The activity of the encoded protein, a G protein-coupled receptor family member, is mediated by G proteins which activate adenylyl cyclase, which induce synthesis of intracellular cAMP. The A2A receptor binds with the Gs protein at the intracellular site of the receptor. The Gs protein consists of three subunits; Gsα, Gsβ and Gsγ. A crystal structure of the A2A receptor bound with the agonist NECA and a G protein-mimic has been published in 2016 (PDB code: 5g53).

The encoded protein (the A2A receptor) is abundant in basal ganglia, vasculature, T lymphocytes, and platelets and it is a major target of caffeine, which is a competitive antagonist of this protein.

Physiological role

A1 and A2A receptors are believed to regulate myocardial oxygen demand and to increase coronary circulation by vasodilation. In addition, A2A receptor can suppress immune cells, thereby protecting tissue from inflammation.

The A2A receptor is also expressed in the brain, where it has important roles in the regulation of glutamate and dopamine release, making it a potential therapeutic target for the treatment of conditions such as insomnia, pain, depression, and Parkinson's disease.

Ligands

A number of selective A2A ligands have been developed,

• with several possible therapeutic applications.

Older research on adenosine receptor function, and non-selective adenosine receptor antagonists such as aminophylline, focused mainly on the role of adenosine receptors in the heart, and led to several randomized controlled trials using these receptor antagonists to treat bradyasystolic arrest.

However the development of more highly selective A2A ligands has led towards other applications, with the most significant focus of research currently being the potential therapeutic role for A2A antagonists in the treatment of Parkinson's disease.

Agonists

• Adenosine
• ATL-146e
• Binodenoson
• Cannabidiol
• CGS-21680
• DPMA (N6-(2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl)adenosine)
• Limonene
• LUF-5833
• NECA (5′-(N-ethylcarboxamido)adenosine)
• Regadenoson
• UK-432,097
• YT-146 (2-octynyladenosine)
• Zeatin riboside

Antagonists

• ATL-444
• Caffeine
• Istradefylline (KW-6002)
• Lu AA41063
• Lu AA47070
• MSX-2
• MSX-3
• Preladenant (SCH-420,814)
• MSX-3
• SCH-58261
• SCH-412,348
• SCH-442,416
• ST-1535
• Theophylline
• VER-6623
• VER-6947
• VER-7835
• Vipadenant (BIIB-014)
• ZM-241,385

Inverse agonists

• KW-6356

Interactions

Adenosine A2A receptor has been shown to interact with Dopamine receptor D2. As a result, Adenosine receptor A2A decreases activity in the Dopamine D2 receptors.

In cancer immunotherapy

The adenosine A2A receptor has also been shown to play a regulatory role in the adaptive immune system. In this role, it functions similarly to programmed cell death-1 (PD-1) and cytotoxic t-lymphocyte associated protein-4 (CTLA-4) receptors, namely to suppress immunologic response and prevent associated tissue damage. Extracellular adenosine gathers in response to cellular stress and breakdown through interactions with hypoxia induced HIF-1α. Abundant extracellular adenosine can then bind to the A2A receptor resulting in a Gs-protein coupled response, resulting in the accumulation of intracellular cAMP, which functions primarily through protein kinase A to upregulate inhibitory cytokines such as transforming growth factor-beta (TGF-β) and inhibitory receptors (i.e., PD-1). Interactions with FOXP3 stimulates CD4+ T-cells into regulatory Treg cells further inhibiting immune response.

Blockade of A2AR has been attempted to various ends, namely cancer immunotherapy. While several A2A receptor antagonists have progressed to clinical trials for the treatment of Parkinson's disease, A2AR blockade in the context of cancer is less characterized. Mice treated with A2AR antagonists, such as ZM241385 (listed above) or caffeine, show significantly delayed tumor growth due to T-cells resistant to inhibition. This is further highlighted by A2AR knockout mice who show increased tumor rejection. Multiple checkpoint pathway inhibition has been shown to have an additive effect, as shown by an increase in response with blockade to PD-1 and CTLA-4 via monoclonal antibodies as compared to the blockade of a single pathway. The A2AR antogonist CPI-444 has shown this in combination with anti-PD-L1 or anti-CTLA-4 treatment as it eliminated tumors in up to 90% of treated mice, including restoration of immune responses in models that incompletely responded to anti-PD-L1 or anti-CTLA-4 monotherapy. Further, tumor growth was fully inhibited when mice with cleared tumors were later rechallenged, indicating that CPI-444 induced systemic antitumor immune memory. Researchers believe that A2AR blockade could increase the efficacy of such treatments even further. Finally, inhibition of A2AR, either through pharmacologic or genetic targeting, in chimeric antigen receptor (CAR) T-cells reveals promising results. Blockade of A2AR in this setting has shown to increase tumor clearance through CAR T-cell therapy in mice. Targeting of the A2A receptor is an attractive option for the treatment of a variety of cancers, especially with the therapeutic success of the blockade of other checkpoint pathways such as PD-1 and CTLA-4.

References

References

1. (May 1989). "Selective amplification and cloning of four new members of the G protein-coupled receptor family". Science.
2. (September 1991). "Chromosomal mapping of A1 and A2 adenosine receptors, VIP receptor, and a new subtype of serotonin receptor". Genomics.
3. (November 2008). "The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist". Science.
4. (July 2012). "Structural basis for allosteric regulation of GPCRs by sodium ions". Science.
5. (February 2006). "Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers". The Journal of Neuroscience.
6. (January 2008). "Adenosine A1-A2A receptor heteromers: new targets for caffeine in the brain". Frontiers in Bioscience.
7. (2005). "Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function". Journal of Molecular Neuroscience.
8. (February 2005). "Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A/D3 heteromeric complexes". Molecular Pharmacology.
9. (March 2008). "The A(2A)-adenosine receptor: a GPCR with unique features?". British Journal of Pharmacology.
10. (2009). "Looking for the role of cannabinoid receptor heteromers in striatal function". Neuropharmacology.
11. (April 2008). "Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis". Neuropharmacology.
12. (November 2007). "Adenosine receptor heteromers and their integrative role in striatal function". TheScientificWorldJournal.
13. (May 2008). "Potential role of adenosine A2A receptors in the treatment of schizophrenia". Frontiers in Bioscience.
14. (2008). "Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions". Current Pharmaceutical Design.
15. (December 2014). "Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment". Cancer Research.
16. (August 2016). "Structure of the adenosine A(2A) receptor bound to an engineered G protein". Nature.
17. "Entrez Gene: ADORA2A adenosine A2A receptor".
18. (2001). "Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage". Nature.
19. (2003). "Adaptations in adenosine signaling in drug dependence: therapeutic implications". Critical Reviews in Neurobiology.
20. (December 2007). "Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications". Progress in Neurobiology.
21. (December 2007). "Adenosine A2A receptors and basal ganglia physiology". Progress in Neurobiology.
22. (December 2007). "Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain". Progress in Neurobiology.
23. (November 2008). "Adenosine A(2A) receptors and their role in drug addiction". The Journal of Pharmacy and Pharmacology.
24. (2008). "Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders". Current Pharmaceutical Design.
25. (September 2008). "Nucleus accumbens adenosine A2A receptors regulate exertion of effort by acting on the ventral striatopallidal pathway". The Journal of Neuroscience.
26. (August 1997). "Aminophylline as an adjunct to standard advanced cardiac life support in prolonged cardiac arrest". Annals of Emergency Medicine.
27. (May 2001). "Effect of aminophylline on complete atrioventricular block with ventricular asystole following blunt chest trauma". Injury.
28. (October 2000). "Aminophylline in the treatment of atropine-resistant bradyasystole". Resuscitation.
29. (March 2003). "A randomized controlled trial of intravenous aminophylline for atropine-resistant out-of-hospital asystolic cardiac arrest". Academic Emergency Medicine.
30. (August 1997). "Adenosine receptor antagonism in refractory asystolic cardiac arrest: results of a human pilot study". Resuscitation.
31. (July 1998). "Successful resuscitation using aminophylline in refractory cardiac arrest with asystole". Resuscitation.
32. (February 1993). "Aminophylline for bradyasystolic cardiac arrest refractory to atropine and epinephrine". Annals of Internal Medicine.
33. (December 2003). "A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD". Neurology.
34. (December 2003). "Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists". Neurology.
35. (November 2005). "New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists". Life Sciences.
36. (January 2009). "The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat". Psychopharmacology.
37. (March 2006). "Adenosine receptors as therapeutic targets". Nature Reviews. Drug Discovery.
38. (April 2015). "Cannabidiol (CBD) and its analogs: a review of their effects on inflammation". Bioorganic & Medicinal Chemistry.
39. (April 2021). "Crystal Structure and Subsequent Ligand Design of a Nonriboside Partial Agonist Bound to the Adenosine A_2A Receptor". Journal of Medicinal Chemistry.
40. (February 2022). "Ribose and Non-Ribose A2A Adenosine Receptor Agonists: Do They Share the Same Receptor Recognition Mechanism?". Biomedicines.
41. (March 1992). "Vasodepressor mechanisms of 2-(1-octynyl)-adenosine (YT-146), a selective adenosine A2 receptor agonist, involve the opening of glibenclamide-sensitive K+ channels". European Journal of Pharmacology.
42. (August 2012). "Time and sex-dependent effects of an adenosine A2A/A1 receptor antagonist on motivation to self-administer cocaine in rats". Pharmacology, Biochemistry, and Behavior.
43. (December 2003). "Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease". Neurology.
44. (May 2009). "The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure". Psychopharmacology.
45. (July 2009). "Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression". The Journal of Pharmacology and Experimental Therapeutics.
46. (March 2001). "Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats". Synapse.
47. (September 2006). "The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets". European Journal of Pharmacology.
48. (June 2023). "In Vitro Pharmacological Profile of KW-6356, a Novel Adenosine A_2A Receptor Antagonist/Inverse Agonist". Molecular Pharmacology.
49. (June 2003). "Oligomerization of adenosine A2A and dopamine D2 receptors in living cells". Biochemical and Biophysical Research Communications.
50. (October 2008). "Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia". Clinical Cancer Research.
51. (April 2015). "A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy". Computational and Structural Biotechnology Journal.
52. (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer.
53. (October 2018). "A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti-PD-(L)1 and Anti-CTLA-4 in Preclinical Models". Cancer Immunology Research.
54. (March 2017). "Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy". The Journal of Clinical Investigation.